We can’t show the full text here under this license. Use the link below to read it at the source.
Once‐weekly glucagon‐like peptide‐1 receptor agonist dulaglutide is non‐inferior to once‐daily liraglutide and superior to placebo in J apanese patients with type 2 diabetes: a 26‐week randomized phase III study
Once-weekly dulaglutide works as well as daily liraglutide and better than placebo in Japanese patients with type 2 diabetes over 26 weeks
AI simplified
Abstract
Once-weekly dulaglutide (0.75 mg) resulted in a 1.57% greater reduction in HbA1c compared to placebo after 26 weeks.
- Dulaglutide was found to be superior to placebo and non-inferior to once-daily liraglutide (0.9 mg) in reducing HbA1c levels.
- The change in HbA1c from baseline was -1.57% for dulaglutide versus placebo and -0.10% for dulaglutide versus liraglutide.
- Common adverse events included nasopharyngitis, constipation, diarrhoea, nausea, abdominal distension, and decreased appetite.
- Decreased appetite was reported significantly more in the liraglutide group compared to the dulaglutide group.
- Hypoglycaemia occurred in 1.8% of patients, with no severe cases reported.
AI simplified
Key numbers
-1.57%
HbA1c Reduction
Difference in HbA1c change from baseline at 26 weeks: dulaglutide vs. placebo.
200 of 280
Proportion Achieving HbA1c <7.0%
Patients on dulaglutide achieving HbA1c <7.0% at 26 weeks.
157 of 280
Adverse Events Incidence
Patients experiencing at least one treatment-emergent adverse event.